Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Flu-like symptoms; After receiving the shot, it was that realized patient received Shingrix in 2018; This non-serious case was reported by a consumer and described the occurrence of influenza-like symptoms in a 77-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received in 2018). Concomitant products included losartan potassium. On 14-MAR-2026, the patient received the 2nd dose of Shingrix. On 14-MAR-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: After receiving the shot, it was that realized patient received Shingrix in 2018). In MAR-2026, the patient experienced influenza-like symptoms (Verbatim: Flu-like symptoms). In MAR-2026, the outcome of the influenza-like symptoms was resolved. The outcome of the drug dose administration interval too long was not applicable. It was unknown if the reporter considered the influenza-like symptoms to be related to Shingrix. It was unknown if the company considered the influenza-like symptoms to be related to Shingrix. Additional Information: GSK Receipt Date: 18-MAR-2026 The batch number was not provided and a request for this information has been made.
LOSARTAN POTASSIUM